Cases & Deals

Forbion Capital leads investment in Xention

Clients Forbion Capital Partners & other entities

Jones Day advised Forbion Capital Partners & other entities in connection with their purchase of Convertible Preferred Stock in a private placement by Xention Limited, a company that engages in the discovery and development of ion channel-modulating drugs in the United Kingdom.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.